Literature DB >> 27919367

Familial partial lipodystrophy presenting as metabolic syndrome.

Darwin Chan1, Adam D McIntyre2, Robert A Hegele2, Andrew C Don-Wauchope3.   

Abstract

We report the first described case of a heterozygous p.R545H (c.1634 G > A) missense mutation in the LMNA gene with clinical features compatible with Dunnigan-type 2 familial partial lipodystrophy (FPLD2). The case presented as metabolic syndrome to a specialist clinical service and highlights the overlap between FPLD2 and the metabolic syndrome. The associations with type 2 diabetes mellitus, fatty liver disease, polycystic ovarian syndrome, and hypertriglyceridemia are highlighted. The importance of evaluating patients for these associated conditions is discussed, and the potential mechanisms of disease are briefly outlined. The mutation has been previously reported in a heart failure database without a clinical description. The links between heart failure and the clinical condition are briefly considered. Copyright Â
© 2016 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dunnigan-type 2 familial partial lipodystrophy; FPLD2; Lamin A/C; Metabolic syndrome

Mesh:

Substances:

Year:  2016        PMID: 27919367     DOI: 10.1016/j.jacl.2016.08.012

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  10 in total

Review 1.  Phenotypic and Genetic Characteristics of Lipodystrophy: Pathophysiology, Metabolic Abnormalities, and Comorbidities.

Authors:  Baris Akinci; Rasimcan Meral; Elif Arioglu Oral
Journal:  Curr Diab Rep       Date:  2018-11-08       Impact factor: 4.810

2.  Assessment of fibroblast nuclear morphology aids interpretation of LMNA variants.

Authors:  Florence H J van Tienen; Patrick J Lindsey; Miriam A F Kamps; Ingrid P Krapels; Frans C S Ramaekers; Han G Brunner; Arthur van den Wijngaard; Jos L V Broers
Journal:  Eur J Hum Genet       Date:  2018-11-12       Impact factor: 4.246

3.  Lipodystrophy and obesity are associated with decreased number of T cells with regulatory function and pro-inflammatory macrophage phenotype.

Authors:  S Berger; G Ceccarini; G Scabia; I Barone; C Pelosini; F Ferrari; S Magno; A Dattilo; L Chiovato; P Vitti; F Santini; M Maffei
Journal:  Int J Obes (Lond)       Date:  2017-07-10       Impact factor: 5.095

4.  LMNA Sequences of 60,706 Unrelated Individuals Reveal 132 Novel Missense Variants in A-Type Lamins and Suggest a Link between Variant p.G602S and Type 2 Diabetes.

Authors:  Alyssa Florwick; Tejas Dharmaraj; Julie Jurgens; David Valle; Katherine L Wilson
Journal:  Front Genet       Date:  2017-06-15       Impact factor: 4.599

Review 5.  Shortcuts to a functional adipose tissue: The role of small non-coding RNAs.

Authors:  Bruna B Brandão; Beatriz A Guerra; Marcelo A Mori
Journal:  Redox Biol       Date:  2017-02-07       Impact factor: 11.799

Review 6.  Long Distance Metabolic Regulation through Adipose-Derived Circulating Exosomal miRNAs: A Trail for RNA-Based Therapies?

Authors:  Farah Fatima; Muhammad Nawaz
Journal:  Front Physiol       Date:  2017-08-02       Impact factor: 4.566

Review 7.  Current Diagnosis, Treatment and Clinical Challenges in the Management of Lipodystrophy Syndromes in Children and Young People

Authors:  Samim Özen; Barış Akıncı; Elif A. Oral
Journal:  J Clin Res Pediatr Endocrinol       Date:  2019-08-22

8.  Phosphorylation of Lamin A/C at serine 22 modulates Nav 1.5 function.

Authors:  Michael A Olaopa; Tomohiko Ai; Bo Chao; Xiangshu Xiao; Matteo Vatta; Beth A Habecker
Journal:  Physiol Rep       Date:  2021-11

Review 9.  Lipodystrophic laminopathies: Diagnostic clues.

Authors:  Cristina Guillín-Amarelle; Antía Fernández-Pombo; Sofía Sánchez-Iglesias; David Araújo-Vilar
Journal:  Nucleus       Date:  2018-01-01       Impact factor: 4.197

10.  Six years' experience with LipidSeq: clinical and research learnings from a hybrid, targeted sequencing panel for dyslipidemias.

Authors:  Jacqueline S Dron; Jian Wang; Adam D McIntyre; Michael A Iacocca; John F Robinson; Matthew R Ban; Henian Cao; Robert A Hegele
Journal:  BMC Med Genomics       Date:  2020-02-10       Impact factor: 3.063

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.